Phase 1/2 study of single-agent Zanubrutinib

 ABSTRACT   06/2020

For more information about this publication, please submit a medical information request.

Phase 1/2 study of single-agent Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service